134 related articles for article (PubMed ID: 21467018)
1. Adult survivors of invasive pneumococcal disease exhibit defective B cell function.
Darton TC; Wing JB; Lees A; Heath AW; Read RC
Clin Infect Dis; 2011 May; 52(9):1133-6. PubMed ID: 21467018
[TBL] [Abstract][Full Text] [Related]
2. Recurrent systemic pneumococcal disease and IRAK4 deficiency.
Turvey SE; Speert DP
Pediatr Infect Dis J; 2007 Nov; 26(11):1074; author reply 1074. PubMed ID: 17984826
[No Abstract] [Full Text] [Related]
3. Pneumococcal surface protein A (PspA) is effective at eliciting T cell-mediated responses during invasive pneumococcal disease in adults.
Baril L; Dietemann J; Essevaz-Roulet M; Béniguel L; Coan P; Briles DE; Guy B; Cozon G
Clin Exp Immunol; 2006 Aug; 145(2):277-86. PubMed ID: 16879247
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and immunogenicity of pneumococcal vaccination in splenectomized and functionally asplenic patients.
Forstner C; Plefka S; Tobudic S; Winkler HM; Burgmann K; Burgmann H
Vaccine; 2012 Aug; 30(37):5449-52. PubMed ID: 22749594
[TBL] [Abstract][Full Text] [Related]
5. The B-cell inhibitory receptor CD22 is a major factor in host resistance to Streptococcus pneumoniae infection.
Fernandes VE; Ercoli G; Bénard A; Brandl C; Fahnenstiel H; Müller-Winkler J; Weber GF; Denny P; Nitschke L; Andrew PW
PLoS Pathog; 2020 Apr; 16(4):e1008464. PubMed ID: 32324805
[TBL] [Abstract][Full Text] [Related]
6. Influenza infection and bacteremic pneumococcal pneumonia.
Blot M; Bruyère R; Chavanet P; Dalle F; Piroth L; Quenot JP; Charles PE
Med Mal Infect; 2019 Sep; 49(6):483-484. PubMed ID: 30961917
[No Abstract] [Full Text] [Related]
7. Protection against Streptococcus pneumoniae Invasive Pathogenesis by a Protein-Based Vaccine Is Achieved by Suppression of Nasopharyngeal Bacterial Density during Influenza A Virus Coinfection.
Khan MN; Xu Q; Pichichero ME
Infect Immun; 2017 Feb; 85(2):. PubMed ID: 27895132
[TBL] [Abstract][Full Text] [Related]
8. A nationwide surveillance of invasive pneumococcal disease in adults in Israel before an expected effect of PCV7.
Regev-Yochay G; Rahav G; Strahilevitz J; Bishara J; Katzir M; Chowers M; Finkelstein R; Chazan B; Zimhony O; Dagan R;
Vaccine; 2013 May; 31(19):2387-94. PubMed ID: 23518404
[TBL] [Abstract][Full Text] [Related]
9. Human monoclonal antibodies isolated from a primary pneumococcal conjugate Vaccinee demonstrates the expansion of an antigen-driven Hypermutated memory B cell response.
Chen Z; Cox KS; Tang A; Roman J; Fink M; Kaufhold RM; Guan L; Xie A; Boddicker MA; Mcguinness D; Xiao X; Li H; Skinner JM; Verch T; Retzlaff M; Vora KA
BMC Infect Dis; 2018 Dec; 18(1):613. PubMed ID: 30509199
[TBL] [Abstract][Full Text] [Related]
10. A Streptococcus pneumoniae Type 2 Oligosaccharide Glycoconjugate Elicits Opsonic Antibodies and Is Protective in an Animal Model of Invasive Pneumococcal Disease.
Emmadi M; Khan N; Lykke L; Reppe K; G Parameswarappa S; Lisboa MP; Wienhold SM; Witzenrath M; Pereira CL; Seeberger PH
J Am Chem Soc; 2017 Oct; 139(41):14783-14791. PubMed ID: 28945368
[TBL] [Abstract][Full Text] [Related]
11. The prevalence and antimicrobial susceptibility of Streptococcus pneumoniae isolated from patients at Jikei University Hospitals after the implementation of the pneumococcal vaccination program in Japan.
Ando T; Masaki T; Kono M; Nagano Y; Sakamoto K; Tamura T; Abe M; Matsushima M; Nakada K; Matsuura T
J Infect Chemother; 2020 Jul; 26(7):769-774. PubMed ID: 32417263
[TBL] [Abstract][Full Text] [Related]
12. Humoral immune responses to Streptococcus pneumoniae in the setting of HIV-1 infection.
Zhang L; Li Z; Wan Z; Kilby A; Kilby JM; Jiang W
Vaccine; 2015 Aug; 33(36):4430-6. PubMed ID: 26141012
[TBL] [Abstract][Full Text] [Related]
13. The Epidemiology and Biostatistics of Pneumococcus.
Oligbu G; Fry NK; Ladhani SN
Methods Mol Biol; 2019; 1968():215-224. PubMed ID: 30929218
[TBL] [Abstract][Full Text] [Related]
14. New vaccines for the prevention of pneumococcal infections.
Käyhty H; Eskola J
Emerg Infect Dis; 1996; 2(4):289-98. PubMed ID: 8969245
[TBL] [Abstract][Full Text] [Related]
15. B cell mediated priming following pneumococcal colonization.
Rabquer B; Shriner AK; Smithson SL; Westerink MA
Vaccine; 2007 Mar; 25(11):2036-42. PubMed ID: 17240006
[TBL] [Abstract][Full Text] [Related]
16. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study.
Farr BM; Johnston BL; Cobb DK; Fisch MJ; Germanson TP; Adal KA; Anglim AM
Arch Intern Med; 1995 Nov; 155(21):2336-40. PubMed ID: 7487259
[TBL] [Abstract][Full Text] [Related]
17. Selective defect of anti-pneumococcal IgG in a patient with persistent polyclonal B cell lymphocytosis.
Hafraoui K; Moutschen M; Smet J; Mascart F; Schaaf-Lafontaine N; Fillet G
Eur J Intern Med; 2009 May; 20(3):e62-5. PubMed ID: 19393481
[TBL] [Abstract][Full Text] [Related]
18. The zwitterionic type I Streptococcus pneumoniae polysaccharide does not induce memory B cell formation in humans.
Trück J; Lazarus R; Clutterbuck EA; Bowman J; Kibwana E; Bateman EA; Pollard AJ
Immunobiology; 2013 Mar; 218(3):368-72. PubMed ID: 22704520
[TBL] [Abstract][Full Text] [Related]
19. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome.
Jansen AG; Rodenburg GD; van der Ende A; van Alphen L; Veenhoven RH; Spanjaard L; Sanders EA; Hak E
Clin Infect Dis; 2009 Jul; 49(2):e23-9. PubMed ID: 19522653
[TBL] [Abstract][Full Text] [Related]
20. Antigen-specific B-cell response to 13-valent pneumococcal conjugate vaccine in asplenic individuals with β-thalassemia previously immunized with 23-valent pneumococcal polysaccharide vaccine.
Papadatou I; Piperi C; Alexandraki K; Kattamis A; Theodoridou M; Spoulou V
Clin Infect Dis; 2014 Sep; 59(6):862-5. PubMed ID: 24879786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
